Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children - Frémond, M-L; Rodero, M P; Jeremiah, N (J Allergy Clin Immunol, 2016)
, et al.